Kansas 2023-2024 Regular Session

Kansas House Bill HB2439

Introduced
2/22/23  
Refer
2/22/23  
Report Pass
3/21/23  
Engrossed
3/29/23  
Refer
3/30/23  

Caption

Requiring notification to patients that the effects of a medication abortion may be reversible.

Impact

This bill will amend existing Kansas laws under the woman's-right-to-know act, specifically adding requirements for patient notifications around medication abortions. It holds healthcare providers to higher disclosure standards and obligates them to inform patients of potential options to reverse medication abortion effects. The bill also has enforcement measures that impose significant fines and potential criminal penalties for non-compliance, thereby aiming to ensure strict adherence by medical practitioners and facilities.

Summary

House Bill 2439 mandates that medical facilities and pharmacies provide clear notifications to patients undergoing medication abortions. Specifically, the bill focuses on the use of mifepristone, a drug commonly used in medical abortions, outlining that patients must be made aware that it may be possible to reverse the effects if they change their mind before taking the second medication. Facilities are required to display this information prominently and ensure patients have access to resources about the reversal procedure.

Contention

Critics of HB 2439 argue that the bill potentially undermines informed consent by inserting controversial information about the reversibility of medication abortions that may not be grounded in strong scientific consensus. Supporters assert that the bill is a necessary measure to ensure women are fully informed about their options when considering an abortion. The bill's stipulations regarding penalties for non-compliance have also raised concerns over undue pressure on healthcare providers and their ability to operate within the bounds of medical ethics.

Companion Bills

No companion bills found.

Similar Bills

CA SB1428

Reproductive health: mifepristone and other medication.

CA AB54

Access to Safe Abortion Care Act.

US HR1285

Condemning the pro-abortion policies of the Biden administration.

US SR510

A resolution expressing the sense of the Senate that the scientific judgement of the Food and Drug Administration that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable and based on science.

NJ SR78

Urges United States Supreme Court to protect freedom of reproductive choice with respect to use of and access to mifepristone.

NJ AR190

Urges United States Supreme Court to protect freedom of reproductive choice with respect to use of and access to mifepristone.

NM HB236

Notice For Medication Abortions

HI HB866

Relating To Health Care.